Pulse Explore Journal Club Debates Trending Researchers Journals

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates | Synapse

October 14, 2020Open Access

View Full Paper

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

EWEdward E. WalshUniversity of Rochester Medical Center RFRobert W. FrenckUniversity of Maryland, Baltimore AFAnn R. FalseyUniversity of Rochester

Key Points

Key points are not available for this paper at this time.

Abstract

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and the United States, support the selection of BNT162b2 for advancement to a pivotal phase 2-3 safety and efficacy evaluation. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).

Ask AI

Helpful

Bookmark

Share

View Full Paper

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Walsh et al. (Wed,) studied this question.

synapsesocial.com/papers/69d777085f9a1dad5349049a https://doi.org/https://doi.org/10.1056/nejmoa2027906

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults2020 · 1,592 citations
2Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine2004 · 429 citations
3NEUTRALIZING ANTIVIRAL B CELL RESPONSES1997 · 485 citations
4Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability2008 · 1,897 citations
5An Infectious cDNA Clone of SARS-CoV-22020 · 772 citations